Stay updated on Pfizer Press Releases
Sign up to get notified when there's something new on the Pfizer Press Releases page.

Latest updates to the Pfizer Press Releases page
- Check2 days agoChange DetectedAdded a new press release entry: 'Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer' (01.10.2026) under Medicines. Removed the item 'Pfizer Completes Acquisition of Metsera' (11.13.2025) from Corporate.SummaryDifference2%

- Check9 days agoChange DetectedJanuary 2026 entries (01.05.2026) were added to the Press Release Archive, and the 11.12.2025 entry was removed. The archive now reflects the latest releases for the start of 2026.SummaryDifference2%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedAdded three December 2025 press releases to the Pfizer Press Release Archive and removed three November 2025 entries.SummaryDifference8%

- Check30 days agoChange DetectedDecember 2025 press releases were added to the archive (Pfizer Declares First-Quarter 2026 Dividend; TUKYSA maintenance therapy update; Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma), and October 2025 items were removed from the archive.SummaryDifference7%

- Check37 days agoChange DetectedAdded a new press release entry under Prescription Medicines for HYMPAVZI® (marstacimab) dated 12.06.2025. Removed the 'Research and Pipeline' category and the press release 'XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer' dated 10.19.2025.SummaryDifference1%

- Check44 days agoChange DetectedAdded Finance and Financial categories and a new press release about Pfizer's December 16 webcast for 2026 financial guidance. Removed two older press releases from the archive.SummaryDifference3%

Stay in the know with updates to Pfizer Press Releases
Enter your email address, and we'll notify you when there's something new on the Pfizer Press Releases page.